NCT04860258 - COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities | Biotech Hunter

Enrollment

129

Participants

Timeline

Start Date

April 22, 2021

Primary Completion Date

September 21, 2021

Study Completion Date

September 21, 2021

Conditions

CoronavirusCovid19SARS-CoV-2Severe Acute Respiratory Syndrome

Interventions

BIOLOGICAL

CVnCoV Vaccine

Intramuscular (IM) injection in the deltoid area, preferably in the non-dominant arm.

Trial Locations (4)

Centre Hospitalier Universitaire Saint-Pierre, Brussels

Université Libre de Bruxelles (ULB) - Hopital Erasme, Brussels

Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc, Brussels

Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman, Liège